News

  • 5 March 2019

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, reported today financial results for the fourth quarter and year ended December 31, 2018, and provided an update on operational initiatives.

  • 28 February 2019

    Genkyotex (Euronext Paris & Brussels: FR0011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces its consolidated financial results for the year ended December 31, 2018 1 , in accordance with International Financial Reporting Standards (IFRS). A summary of the consolidated financial statements is included below.

  • 27 February 2019

    Genkyotex (Euronext Paris & Brussels: FR0011790542 – GKTX) a biopharmaceutical company and the leader in NOX therapies, today announced the launch of the reverse stock split, as approved by Genkyotex’ shareholders at the January 24, 2019 Extraordinary General Meeting. 

  • 27 February 2019

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical stage biotechnology company advancing innovative therapeutics to improve ocular health, today announces that the first patients have been dosed in the THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease.

  • 26 February 2019

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of pivotal clinical data from the ARTISAN-SNM pivotal clinical study designed to gain marketing approval from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System1.